HSP90AA1 and neoplasm: Given the specific supporting role of eHsp90α in cancer, and the failure of many clinical trials using pan- inhibitors targeting all intracellular Hsp90 chaperone members, several groups have reported on the benefit of selectively inhibiting eHsp90α for reducing tumour metastasis and improving patient survival.